

**AMENDMENTS TO THE CLAIMS**

Please replace the claims, including all prior versions, with the listing of claims below.

**LISTING OF CLAIMS:**

1-36. (cancelled)

37. (new): A method of treating or managing cancer comprising:  
administering to a patient a pharmaceutical composition comprising an effective amount  
of mycobacterium w or constituents of mycobacterium w.

38. (new): The method of claim 37, wherein the method is for decreasing the burden of  
cancer tissue.

39. (new): The method of claim 37, wherein the method is for improving the cancer  
treating effect of radiotherapy or chemotherapy.

40. (new): The method of claim 37, wherein the method is for reducing the side-effects  
of radiotherapy or chemotherapy.

41. (new): The method of claim 40, wherein the side effects are hematological side  
effects.

42. (new): The method of claim 40, wherein the side effects are reduced to avoid  
postponement of chemotherapy.

43. (new): The method of claim 40, wherein the side effects are leucopenia,  
thrombocytopenia, anaemia, nausea, vomiting or mucositis.

44. (new): The method of claim 37, wherein the mycobacterium w is dead mycobacterium w.

45. (new): The method of claim 44, wherein the mycobacterium w has been killed by a physical method.

46. (new): The method of claim 45, wherein the physical method is the application of heat.

47. (new): The method of claim 46, wherein the heat is applied by means of autoclaving.

48. (new): The method of claim 37, wherein the pharmaceutical composition comprises constituents of mycobacterium w that have been obtained by sonication.

49. (new): The method of claim 37, wherein the pharmaceutical composition comprises constituents of mycobacterium w that have been obtained by extraction.

50. (new): The method of claim 49, wherein the constituents of mycobacterium w have been extracted by organic solvents.

51. (new): The method of claim 50, wherein the organic solvents are selected from the group consisting of chloroform, ethanol, methanol, acetone, phenol, isopropyl alcohol, acetic acid, urea and hexane.

52. (new): The method of claim 37, wherein the pharmaceutical composition further comprises one or more adjuvants.

53. (new): The method of claim 52, wherein the pharmaceutical composition further comprises a surfactant.

54. (new): The method of claim 53, wherein the surfactant is polyoxyethylene (20) sorbitan monooleate.

55. (new): The method of claim 53, wherein the pharmaceutical composition comprises a surfactant in an amount up to 0.4% by weight/volume of the pharmaceutical composition.

56. (new): The method of claimer 53, wherein the pharmaceutical composition comprises a surfactant in an amount up to 0.1% by weight/volume of the pharmaceutical composition.

57. (new): The method of claim 37, wherein the mycobacterium w is urease negative, does not hydrolyse polyoxyethylene (20) sorbitan monooleate , does not produce niacin, and provides a strong positive response to nitrate reduction tests.

58. (new): The method of claim 37, wherein the pharmaceutical composition is administered alone or in combination with other modes of therapy.

59. (new): The method of claim 37, wherein the pharmaceutical composition is administered by parenteral route.

60. (new): The method of claim 37, wherein the pharmaceutical composition is administered by intramuscular, subcutaneous or intradermal route.

61. (new): The method of claim 37, wherein the pharmaceutical composition is in a unit dosage form comprising at least  $10^5$  mycobacterium w.

62. (new): The method of claim 37, wherein the pharmaceutical composition is in a unit dosage form comprising at least  $10^7$  mycobacterium w.

63. (new): The method of claim 37, wherein the pharmaceutical composition is in a unit dosage form comprising from  $10^8$  to  $10^{10}$  mycobacterium w.

64. (new): The method of claim 37, wherein the pharmaceutical composition further comprises a preservative.

65. (new): The method of claim 37, wherein the cancer is a primary or a secondary (metastatic) lesion.

66. (new): A method of improving the quality of life in a patient suffering from cancer comprising:

administering to a patient a pharmaceutical composition comprising an effective amount of mycobacterium w or constituents of mycobacterium w.

67. (new): The method of claim 66, wherein the improvement in quality of life is obtained in the absence of other modes of treatment.

68. (new): The method of claim 66, wherein the improvement in quality of life is obtained with the addition of other modes of treatment.

69. (new): A method of amelioration of symptoms associated with cancer comprising:  
administering to a patient a pharmaceutical composition comprising an effective amount of mycobacterium w or constituents of mycobacterium w.